Sertad4's role in harmful heart scarring after a heart attack
The role of Sertad4 in pathologic cardiac remodeling.
['FUNDING_R01'] · OHIO STATE UNIVERSITY · NIH-11125764
This project looks at whether blocking a protein called Sertad4 can stop fibroblasts from causing the scarring that weakens the heart after a heart attack.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OHIO STATE UNIVERSITY (nih funded) |
| Locations | 1 site (Columbus, UNITED STATES) |
| Trial ID | NIH-11125764 on ClinicalTrials.gov |
What this research studies
Researchers will use molecular tools and lab models to see how Sertad4 controls gene programs in cardiac fibroblasts that drive scarring. They will use BRD4 as a guide to find disease-activated targets and then focus on Sertad4 because it is active in fewer cell types. The team will test whether turning down or blocking Sertad4 in animals limits fibroblast activation and preserves heart function after experimentally induced heart attacks. The work is based at Ohio State with collaborators and aims to produce findings that could move toward human testing in the future.
Who could benefit from this research
Good fit: People who have had a myocardial infarction (heart attack) or who are developing ischemic heart failure would be the most relevant candidates for future trials based on this work.
Not a fit: Patients whose heart disease is not driven by fibroblast-mediated scarring or those who are not eligible for clinical trials may not benefit from this line of research.
Why it matters
Potential benefit: If successful, this work could lead to therapies that reduce harmful scarring after heart attacks and help preserve heart function.
How similar studies have performed: Previous work targeting broad regulators like BRD4 showed benefit in lab models but raised safety concerns, so focusing on a more selective protein like Sertad4 is a newer and less-tested approach.
Where this research is happening
Columbus, UNITED STATES
- OHIO STATE UNIVERSITY — Columbus, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: STRATTON, MATTHEW — OHIO STATE UNIVERSITY
- Study coordinator: STRATTON, MATTHEW
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.